SequelSEC

PULSE BIOSCIENCES, INC. PLSE

Surgical & Medical Instruments & Apparatus · CIK 0001625101 · Fiscal year ends 1231

Revenue
$1.18M
Fiscal year ended 2026-06-30
Operating income
-$83.04M
Fiscal year ended 2026-06-30
Free cash flow
-$61.39M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$394.34MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$5.78Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1126.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity4.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue12777.4%100th
SBC / revenue6130.6%100th
Net margin-20794.6%1th
FCF margin-15553.4%1th
Operating margin-21982.6%2th
Gross margin-54.0%2th
CapEx / revenue90.0%95th
Current ratio10.53x93th
Effective tax rate0.0%15th

PULSE BIOSCIENCES, INC. (PLSE) reported revenue of $1.18M and net income of -$80.06M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from PULSE BIOSCIENCES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

PULSE BIOSCIENCES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$1.18M
Cost of revenue$1.18M
Gross profit$3.00K
Operating income-$83.04M
Net income-$80.06M
Research & development$51.89M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$31.16M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

PULSE BIOSCIENCES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$101.62M
Total assets$115.56M
Current assets$105.70M
Total liabilities$16.06M
Current liabilities$10.98M
Total equity incl. NCI$99.50M
Temporary (mezzanine) equityUnavailable
Inventory$236.00K
Accounts receivable$122.00K
Goodwill$2.79M
Long-term debtUnavailable
Accounts payable$2.83M

Cash flow

PULSE BIOSCIENCES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$61.10M
Capital expenditures$290.00K
Investing cash flow-$290.00K
Financing cash flow$56.66M
Net change in cash-$4.73M
Stock-based compensation$17.47M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

PULSE BIOSCIENCES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$61.39M
Gross margin0.3%
Operating margin-7007.8%
FCF margin-5180.4%
SBC / revenue1474.4%
Current ratio9.63x
Revenue YoY growthUnavailable
Net margin-6755.8%
R&D / revenue4378.6%
CapEx / revenue24.5%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PLSE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.